• Explore /
  • Poster
  • / Evidence that neoadjuvant anthracycline based combination chemotherapy (NACT) in breast cancer (BC) induces phenotypical changes which guides the optimal adjuvant therapy.

Evidence that neoadjuvant anthracycline based combination chemotherapy (NACT) in breast cancer (BC) induces phenotypical changes which guides the optimal adjuvant therapy.

Abstract Poster

Authors

null

Tarek Mohamed Ahmed Abdel-Fatah

Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom

Tarek Mohamed Ahmed Abdel-Fatah , Rebekah Webb , Ruizhe Li , Xin Chen , Elisabetta Giannotti , Dorothee Auer , Jennifer Walker , Paul M Moseley , A. Graham Pockley , Graham Ball , Ian O. Ellis , Emad Rakhah , Zsolt Hodi , Andrew Lee , Arlene Chan , Stephen Chan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Neoadjuvant Therapy

Citation

J Clin Oncol 37, 2019 (suppl; abstr 590)

DOI

10.1200/JCO.2019.37.15_suppl.590

Abstract #

590

Poster Bd #

82

Abstract Disclosures

Similar Posters

First Author: Tarek Mohamed Ahmed Abdel-Fatah

Poster

2017 ASCO Annual Meeting

Subgroup efficacy evaluation of the AE37 HER2 vaccine in breast cancer patients in the adjuvant setting.

Subgroup efficacy evaluation of the AE37 HER2 vaccine in breast cancer patients in the adjuvant setting.

First Author: Kaitlin M. Peace

First Author: Takashi Ishikawa

First Author: Ahmet Bilici